Novavax

Producing next-generation vaccines to help protect health through partnerships and R&D. See what’s developing at &

[Novavax @Novavax]

Through our partners including @sanofi, our vaccine technology continues to reach people around the globe and our strategy of partnerships and R&D innovation continues to drive near-term value. Read more: https://t.co/rmFcmfxyC1

[Novavax @Novavax]

Join us Thursday, November 5, as we report our third quarter financial results for 2026 and share key operational highlights.

Get the details and register here: https://t.co/aaro3zpSPO

#Earnings #FinancialResults

[Novavax @Novavax]

This week, members of our leadership team will participate in a couple of investor conferences, discussing the progress we’re making on our corporate growth strategy and what’s ahead.

Learn more about our upcoming events: https://t.co/IW5vr33Dgu

[Novavax @Novavax]

#NEWS: Novavax continues to deliver through our partnerships with @sanofi and Takeda, with Nuvaxovid™ approvals in the U.S., European Union and Japan for the 2026-2027 vaccination season.

Read more: https://t.co/Ps609LHIAG

[Novavax @Novavax]

We’re sharing our second quarter 2026 financial results today, highlighting continued progress on our corporate growth strategy.

Join our live call at 8:30 a.m. ET: https://t.co/717WDPIBs6

Read the full press release: https://t.co/9q59xQf37U

#Earnings #FinancialResults

[Novavax @Novavax]

Join us Thursday, August 6, as we report our second quarter financial results for 2026 and share key operational highlights.

Get the details and register here:  https://t.co/Mh65FLUJIm

#Earnings #FinancialResults

[Novavax @Novavax]

This week, members of our leadership team will participate in a fireside chat at the @BofA_Business Securities Health Care Conference, where they’ll discuss our corporate growth strategy.

Register for the webcast: https://t.co/C6LdLr5ZYx

#PoweringWhatsPossible

[Novavax @Novavax]

Today, we’re sharing our first quarter 2026 financial results including the continued progress on our corporate growth strategy. Join our live call at 8:30 a.m. ET: https://t.co/xu0fk4ima7

Read the full press release: https://t.co/ZaZ0xmMhLH

#Earnings #FinancialResults

[Novavax @Novavax]

Join us Wednesday, May 6 as we report our first quarter financial results for 2026 and share key operational highlights.

Get the details and register here:  https://t.co/xQLA1IM20u

#Earnings #FinancialResults

[Novavax @Novavax]

Today, we’re sharing our Q4 and FY 2025 financial results and the continued progress on our corporate strategy. Join our live call starting at 8:30 a.m. E.T. here: https://t.co/CX48fibdYV

Full press release: https://t.co/lmeWMqSVS3

[Novavax @Novavax]

Join us next Thursday, February 26 as we report our fourth quarter and full year 2025 financial results and share key operational highlights.

More information: https://t.co/MLzlXNj4rA

#Earnings #FinancialResults

[Novavax @Novavax]

#NEWS: Novavax has entered into a non-exclusive license agreement with @pfizer for use of Novavax’s Matrix-M® adjuvant for up to two disease areas.

This new partnership shows our corporate strategy in action, and adds to the successful collaboration we have with Sanofi, among other major companies. We’re excited to be executing on our strategy to drive incremental value from partnerships and R&D innovation, with the potential to create new or improve existing products using Novavax’s differentiated technology platform. Ultimately, these partnerships increase access for the people who could benefit from products built with our technology and importantly drive incremental value for investors and for global public health.

Visit https://t.co/Hr9DmSqCl8 to get details on the potential value we are building with this partnership, including $30 million upfront, up to $500 million in milestone payments and more.

We’re excited to work with you, Pfizer.

Read more: https://t.co/TZeb8QqpPw

[Novavax @Novavax]

We’re looking forward to attending this year’s @jpmorgan Healthcare Conference.

Learn more: https://t.co/dU0qPVMLDK

[Novavax @Novavax]

#NEWS: Novavax completes U.S. marketing authorization transfer to @Sanofi for Nuvaxovid™, following the EU transfer in October in line with its collaboration and license agreement as well as its corporate strategy. https://t.co/Sij8kSkPka

[Novavax @Novavax]

#NEWS: Novavax executes planned site consolidation, further reducing cost footprint in line with our corporate strategy. Learn more: https://t.co/OlLJojTJSZ

[Novavax @Novavax]

This #HealthLiteracyMonth, we’re sharing accessible information on vaccines to empower people to make informed health decisions. Building #HealthLiteracy is essential to address uncertainties, strengthen confidence and ultimately improve global health. Watch to learn more.

[Novavax @Novavax]

#NEWS: Novavax continues to deliver on @Sanofi partnership, completing Nuvaxovid® EU marketing authorization transfer. https://t.co/QKmi2lyfBi

[Novavax @Novavax]

Novavax has further deepened its partnership with Sanofi, announcing an expansion of Sanofi’s license to include the use of Matrix-M® adjuvant in Sanofi’s pandemic influenza vaccine candidate program, supported by recent BARDA funding.

Read more: https://t.co/Z6HA7h9b6o

[Novavax @Novavax]

@writingdisabled Hello, thank you for your comment. Please visit https://t.co/Gcfb6Fc57F to report your experience or potential side effects.

[Novavax @Novavax]

@ananke360 Hello, thank you for your comment. Please visit https://t.co/Gcfb6Fc57F to report your experience or potential side effects.